Merus’ (MRUS) “Buy” Rating Reiterated at Guggenheim

Guggenheim reissued their buy rating on shares of Merus (NASDAQ:MRUS) in a research report released on Tuesday,Benzinga reports. They currently have a $109.00 price objective on the biotechnology company’s stock.

A number of other brokerages have also recently issued reports on MRUS. Bank of America lowered their price objective on Merus from $73.00 to $70.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. Citigroup upped their price target on Merus from $89.00 to $97.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Piper Sandler began coverage on Merus in a research report on Thursday, February 13th. They set an “overweight” rating and a $84.00 price target on the stock. Wells Fargo & Company began coverage on Merus in a research report on Friday, February 7th. They set an “overweight” rating and a $91.00 price target on the stock. Finally, The Goldman Sachs Group began coverage on Merus in a research report on Thursday, November 21st. They set a “buy” rating and a $73.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $85.31.

Merus Stock Performance

Shares of Merus stock opened at $48.31 on Tuesday. Merus has a 52-week low of $37.77 and a 52-week high of $61.61. The stock’s 50-day simple moving average is $43.27 and its 200 day simple moving average is $46.27. The stock has a market capitalization of $3.34 billion, a P/E ratio of -12.23 and a beta of 1.15.

Merus (NASDAQ:MRUS) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The business had revenue of $9.14 million for the quarter, compared to analysts’ expectations of $10.57 million. Equities research analysts forecast that Merus will post -3.85 EPS for the current fiscal year.

Institutional Trading of Merus

Hedge funds and other institutional investors have recently bought and sold shares of the company. State of Wyoming purchased a new stake in Merus in the fourth quarter worth approximately $48,000. Wells Fargo & Company MN boosted its stake in Merus by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock worth $59,000 after buying an additional 300 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Merus in the fourth quarter worth approximately $60,000. Avior Wealth Management LLC purchased a new stake in Merus in the fourth quarter worth approximately $76,000. Finally, Lazard Asset Management LLC purchased a new stake in Merus in the fourth quarter worth approximately $84,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.